rs9843304 in TM4SF4 (OR, 1.12; 95% CI, 1.08-1.16; P ¼ 6.09 Â 10 -11 ), rs2547231 in SULT2A1 (encodes a sulfoconjugation enzyme that acts on hydroxysteroids and cholesterol-derived sterol bile acids) (OR, 1.17; 95% CI, 1.12-1.21; P ¼ 2. 24 Â 10 -10 ), rs1260326 in glucokinase regulatory protein (OR, 1.12; 95% CI, 1.07-1.17; P ¼ 2.55 Â 10 -10 ), and rs6471717 near CYP7A1 (encodes an enzyme that catalyzes conversion of cholesterol to primary bile acids) (OR, 1.11; 95% CI, 1.08-1.15; P ¼ 8. 84 Â 10 -9 ). Among individuals of African American and Hispanic American ancestry, rs11887534 and rs4245791 were associated positively with gallstone disease risk, whereas the association for the rs1260326 variant was inverse. CONCLUSIONS: In this large-scale GWAS of gallstone disease, we identified 4 loci in genes that have putative functions in cholesterol metabolism and transport, and sulfonylation of bile acids or hydroxysteroids.
Keywords: Genetics; Risk Factors; SNP; GWAS.
A ccounting for a substantial clinical burden in the United States, gallstone disease afflicts 6.3 million men and 14.2 million women between the ages of 20 and 74 years, leading annually to 700,000 cholecystectomies and an economic burden of 6.5 billion dollars. 1 It was hypothesized as early as the 1960s that the composition of bile may play an important role in gallstone formation. 2 Bile is formed by the transportation of cholesterol, bile acids, and other organic molecules such as bilirubin from within the hepatocytes to the biliary canaliculi, and serves as a medium for excretion of lipid-soluble products of metabolism. Precipitation of biliary constituents from their soluble state into their insoluble form initiates the process of gallstone formation. Clinical conditions with chronic hemolytic states such as sickle cell disease frequently have been associated with pigmented gallstones 3 as a result of the increased delivery of unconjugated bilirubin into the bile via hepatocytes. 4 However, the most common (80%-90%) constituent of gallstones retrieved during cholecystectomy surgery or autopsy is biliary cholesterol. Studies that compared the constituents of lithogenic bile and normal bile observed that higher concentrations of cholesterol, or the alterations in relative proportions of other bile components such as bile salts and phospholipids, can result in supersaturation of cholesterol. 2, 5 Redinger and Small 6 further showed a correlation between the percentage saturation of biliary cholesterol in various ethnic groups and estimated gallstone prevalence rates in the same population in an ecologic study. Consequently, several lifestyle determinants such as female sex, greater parity, postmenopausal hormone therapy, Native American ancestry, high body mass index (BMI), and dyslipidemia are among the most important risk factors for gallstone disease, primarily because of their influence on cholesterol concentration in the bile. 5, 7 Based on familial clustering of gallstone disease, a 2-to 3-fold increased risk among first-degree relatives, [8] [9] [10] and heritability estimates of 25%-29% from twin studies, 10, 11 it has been suggested that genetic factors may play an important contributory role in cholelithiasis. More evidence to support this hypothesis was established using experimental crosses of inbred mice strains with varying prevalence of gallstones. 12, 13 Quantitative trait loci-based approaches were used to generate a murine gallstone genetic map of several candidate lithogenic (lith) loci, 12, 14 with the idea that orthologous human LITH genes may be predicted owing to homology between human and mouse genomes. These murine lith loci co-localized with approximately 7 "likely," and approximately 20 "plausible" candidate genes for gallstone disease, many of which are involved in cholesterol (eg, ABCG5/ABCG8) and bile acid (eg, ABCB11) synthesis, transport, or metabolism. 13 The identification of genetic risk factors of gallstone disease in human beings was undertaken in 2007 in a discovery-based genome-wide association study (GWAS) of 280 cases and 360 controls. 15 This study identified and replicated an approximately 2-fold increased risk for carriers of the H-allele of D19H in the hepatic cholesterol transporter gene ABCG8 (rs11887534; risk allele frequency, w7%). 15, 16 Other studies that examined genetic associations with gallstone disease were based on biological insights of candidate loci or pathways. Buch et al 17 investigated the association of known bilirubin loci 18 with the incidence of gallstone disease, and observed a recessive mode of inheritance at the UGT1A1 SNP locus rs6742078, finding that carriers of the T/T genotype were predisposed to an increased risk of gallstone disease among men, but not among women. 17 Moreover, a recent study in women, examining associations of approximately 2000 gene-centric loci in known lipid metabolism and obesity pathways, 19 reported additional associations for the glucokinase regulatory protein (GCKR) SNP rs1260326 and the TTC39B SNP rs686030 with gallstone disease; however, these associations were not replicated.
Although there is strong evidence for genetic contribution toward the risk of gallstone disease, there are few replicated susceptibility loci identified from genome-wide, discovery-based approaches because of the limited size and scope of prior studies. In this study, we therefore conducted a large-scale GWAS meta-analysis in individuals with pre-existing genetic data on more than 2 million genetic variants, to discover additional loci associated with the risk
Statistical Analysis
Within each discovery study, we estimated the association between genotyped or imputed single-nucleotide polymorphisms (SNPs) and the risk of gallstone disease by calculating b coefficients and their standard errors using logistic regression models adjusted for age, sex, and additional studyspecific covariates, assuming log-additive genetic effects. Before meta-analyses, we excluded imputed SNPs with imputation quality score and/or imputation R 2 < 0.3. We also used a minor allele frequency (MAF) filter, excluding SNPs with a MAF less than 0.01 for cohorts with more than 500 cases. For cohorts with fewer than 500 cases, we used a more stringent MAF threshold of 5, divided by the number of cases, thereby limiting analysis to SNPs expected to have 10 or more minor alleles within cases, to obtain robust estimates. Inverse variance weighted, fixed-effects, meta-analysis 30 of study-specific estimates was performed to identify SNPs associated with gallstone disease, using METAL (http://genome.sph.umich.edu/ wiki/METAL_documentation). We selected the strongest independent markers at each locus to attempt replication as well as to aid in functional/molecular interpretation, by performing conditional analyses in genomic regions (10 megabase windows using a less-stringent nominal significance threshold for SNPs [discovery P < 5 Â 10 -6 ]), using genome-wide complex trait analysis software 31 (http://www. complextraitgenomics.com/software/gcta/). Conditional analysis is a mechanism to try to reduce the number of significant associations to the top most independent associations. We used 1753 healthy controls of European ancestry from the type 2 diabetes data set within the NHS as the reference population. Replication was performed for SNPs that were observed to be associated with gallstone disease risk at a genome-wide significance threshold of P less than 5 Â 10 -8 after conditional analysis. We genotyped newly identified SNPs using the TaqMan (Applied Biosystems Inc, Foster City, CA) or KASPar (KBiosciences, Hoddesdon, Hertfordshire, UK) assay in the replication data sets, except the NHS and HPFS studies, in which we had pre-existing genotype/imputation data. We reported fixed-effects, meta-analytic odds ratios (ORs) and 95% confidence intervals (CIs) for combined associations from discovery and replication studies for all of the replicated SNPs. The heterogeneity of effect sizes between studies was determined using Cochran's Q-test for heterogeneity 32 as implemented in METAL, 30 and also by determining the I 2 statistics 33 that compute the proportion of overall variance that can be attributed as a result of differences in effect sizes between studies. For these SNPs, if discovery studies showed an evidence of heterogeneity (P < .05), we reported association results using random-effects meta-analysis in the combined discovery and replication studies.
In the replication studies, we additionally determined the strength of association for unit of SD increase in the weighted genetic risk score with gallstone disease risk. For the purpose of developing a genetic risk score, SNPs with missing information within the replication data sets were imputed by random sampling with replacement, from individuals with the SNP information available, and conditional on case-control status. We derived a genetic risk score for each study participant by assigning weights to each risk allele proportional to the logarithm of per-allele relative risk estimate in the metaanalysis of discovery studies. The weighted genetic risk score (GRS) was standardized to have a zero mean and unit SD.
We performed a sensitivity analysis to exclude possible genetic associations mediated by BMI. Logistic regression models in each of the discovery studies were used to obtain b coefficients and standard errors, after adjusting for BMI in addition to age and sex, followed by a meta-analysis of studyspecific effect size estimates.
Post Hoc Analysis
We performed ancestry-specific analyses to determine whether any of the variants with P less than 5 Â 10 -8 in the discovery and replication data sets showed an association in African American or Hispanic American individuals, and whether they showed differences in allelic frequencies across populations. Analysis was performed in individuals of African American ancestry for 115 prevalent gallstone disease cases and 2484 controls in the ARIC cohort, and for 1384 incident and prevalent cases and 6661 controls in the WHI cohort. Effect size estimates for Hispanic American ethnicity was performed From the discovery GWAS meta-analyses summary statistics we determined the following associations: (1) known nonalcoholic fatty liver disease variants, (2) previously reported variants associated with gallstone disease that did not reach genome-wide significance in our data sets (UGT1A1 rs6742078 and TTC39B SNP rs686030), and (3) overlap with lith genes described from murine models. [12] [13] [14] In post hoc analysis within the NHS and HPFS cohorts, for SNPs with P less than 5 Â 10 -8 , we computed genotype-specific associations with gallstone disease, and percentage population attributable risk for each genotype, as described previously. 17 In addition, we tested for associations for these SNPs assuming different modes of inheritance (recessive and dominance effects), and for gene-gene interactions between these SNPs. For multiple independent associations at the same genetic locus (ABCG8 SNPs), we tested for associations of each haplotype combination with gallstone disease risk. We also evaluated for confounding effects of history of self reported hypercholesterolemia, use of cholesterol-lowering drugs (ever/ never), and postmenopausal hormone use (ever/ never).
RNA Sequencing of Human Gallbladder
We performed RNA sequencing from 4 human gallbladders (3 healthy controls and 1 patient with chronic gallstones) and 1 liver sample from the gallstone patient. RNA was obtained from gallbladder and liver of 1 woman, age 71 years, with chronic cholecystitis and metastatic adenocarcinoma consistent with primary colon cancer (OriGene, Technologies, Inc, Rockville, MD CU0000000466). RNA also was obtained from 3 normal gallbladder samples, all women (ages 34, 46, and 64 years) (BioChain Institute, Inc, Hayward, CA, lot numbers A509245, A607331 and A509248 respectively).
RNA Seq libraries were prepared using Ovation RNAseq v2 (NuGEN Technologies, Inc, San Carlos, CA), following the guidelines for the Ovation SP Ultralow DR Multiplex System (NuGEN Technologies, Inc, San Carlos, CA). Library quality was verified for each sample using MiSeq (Illumina, Inc, San Diego, CA), sequencing with 75-bp paired-end reads. Samples next were sequenced using an Illumina HiSeq 2000 instrument (Illumina, Inc) with 75-bp paired-end reads. The raw reads in fastq format were mapped to human genome hg19 using Tophat (v2.0.9) with the following parameter setting: -g 1, -N 2, -r 200. RefSeq transcripts read count and reads per kilobase of transcript per million were calculated using RSeQC (v2.3.6). The runs generated an average of 4,063,889 uniquely mapped reads per sample, with good mapping rates: cholecystitis gallbladder (89.5% uniquely mapped), cholecystitis liver (83.8%), and normal gallbladder samples (96.0%, 96.1%, and 84.9%, respectively). These data are available through GEO accession number GSE66430 (http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc¼GSE66430).
Expression Quantitative Trait Loci and Encyclopedia of DNA Elements (ENCODE) Regulatory Analyses
Proxy SNPs in linkage disequilibrium (r 2 > 0.8) in populations of European ancestry were identified for gallstone index and replication SNPs using SNAP (http://www.broadinstitute. org/mpg/snap/). 34 Index SNPs and proxies were queried against a collected database of expression SNP (eSNP) results. The collected eSNP results met the criteria for statistical thresholds for association with gene transcript levels as described in the original article. 35 A general overview of a subset of more than 50 expression quantitative trait loci (eQTL) studies has been published. 35 We assessed the concordance of the gallstone-identified eSNPs with the strongest eSNPs for each individual gene and data set using linkage disequilibrium metrics (R 2 ) and report the results for either the index SNP or SNPs in linkage disequilibrium with R 2 greater than 0.8. The resulting eQTL SNPs with gene expression associations with P less than 5 Â 10 -6 were queried for overlap with ENCODE regulatory features using HaploReg v3 (http://www.broadinstitute.org/ mammals/haploreg/haploreg_v3.php). 36 More details on eQTL and ENCODE regulatory analyses methods are available in the Supplementary Materials and Methods section.
Prior GWAS Phenotype Analysis
Gallstone index and replication SNPs and their proxies (as defined earlier) were queried against the National Heart, Lung, and Blood Institute Genome-wide Repository of Associations between SNPs and Phenotypes, version 2.0.0.0 (http://apps. nhlbi.nih.gov/grasp). Only results with a P value less than 5 Â 10 -8 were retained. The strongest SNP per GWAS phenotype per gallstone locus was reported.
Results

Meta-analysis
Fixed-effects meta-analysis, 30 followed by conditional analyses within nominally significant regions 31 (10 Mb windows around SNPs with P < 5 Â 10 -6 ), yielded 7 SNPs from 5 genome-wide significant regions: ABCG5/8, TM4SF4, SULT2A1, UBXN2B/CYP7A1, and GCKR, independently associated with gallstone disease (P < 5 Â 10 -8 ) (Table 2, Figure 1 , and Supplementary Table 2 ). There was no evidence of inflation of test statistics in the genome-wide meta-analysis (l ¼ 1.037; Q-Q plot in Supplementary Figure 2) . The newly discovered SNPs had high imputation quality scores (>0.80) in each of the discovery studies (Supplementary Table 3 ). A sensitivity analysis adjusting for BMI before meta-analyses (to exclude genetic associations potentially mediated by BMI) yielded results that did not differ materially from those presented in Table 2 (Supplementary Table 4 ). Regional association plots for the 5 independent loci are shown in Supplementary  Figure 3 . Except for the ABCG5 and ABCG8 loci, SNPs with a P value of less than 1 Â 10 -4 in our discovery samples did not map to human orthologs of the candidate lith genes proposed in murine models. Although we did not observe a genomewide significance for previously reported TTC39B SNP rs686030, 19 the A allele at the locus showed some evidence for an increased risk of gallstone disease (OR, 1.09; P ¼ .000438).
Replication
We selected 6 SNPs (rs11887534 and rs4245791
, and rs1260326 [GCKR]) for replication (Table 2 ) and for subsequent functional analyses (Table 3 ). For replication, we utlized an independent sample of 6489 cases and 62,797 controls from 3 population-based studies and a case-control study ( Table 1 ). The ABCG8 SNP rs4245791 (P-discovery ¼ 1.90 Â 10 -34 , R 2 ¼ 1.0 with rs4299376), and SULT2A1 SNP rs2547231 (P-discovery ¼ 2.24 Â 10 -10 , R 2 ¼ 0.90 with rs296391), have been shown previously to be associated strongly with hepatic ABCG8 37 and SULT2A1 38 expressions, respectively, and therefore were selected for replication instead of the index SNPs. All of the selected SNPs were associated significantly with gallstone disease in meta-analysis from replication data sets. To account for heterogeneity of effect estimates for the ABCG8 locus SNP rs11887534 and for the UBXN2B/CYP7A1 SNP rs6471717 in the discovery meta-analysis, we report their effect sizes using both fixed-and random-effects metaanalysis in the combined discovery and replication analyses ( Table 2 and Figure 2 ). The fixed-and random-effects P value for rs6471717 in combined discovery and replication analyses were 1.41 Â 10 -13 and 1.59 Â 10 -7 , respectively. It is likely that evidence of heterogeneity reflects differences in magnitude of effect sizes of the susceptibility locus, possibly owing to differences in study design or participant characteristics. However, the direction of effect was consistent for all replication SNPs across the studies (Figure 2 ). GRSs based on the 6 replicated SNPs and weighted on discovery stage b estimates were associated with an approximately 35% increased risk of gallstone disease for unit of SD increase in GRS in all replication studies and provided modest improvement in the area under the receiver operator characteristic curve (Supplementary Table 5 and Supplementary Figure 4) .
SNP Associations in African American and Hispanic American Populations
We observed that 3 SNPs from 2 loci-rs1260326, rs11887534, and rs4245791-were associated significantly (P < .05) with gallstone disease among African American and Hispanic American individuals (Table 4) . However, the direction of association was opposite to what we observed in the European population for rs1260326. We did not observe an association in these ethnicities for rs9843304, rs6471717, or rs2547231 SNPs. Moreover, we also observed marked differences in allele frequencies, for example, the T allele at rs1260326 is the major allele in individuals of European ancestry (frequency, 0.59), but the minor allele in African American individuals (frequency, 0.14) and individuals of Hispanic American ancestry (frequency, 0.22). Similarly, the C allele at rs9843304 has a frequency of 0.45 in individuals of European ancestry, but has a frequency of approximately 0.8 in African Americans and 0.42 in Hispanic Americans.
Post Hoc Analyses
Supplementary Table 6 shows the associations for dominant and recessive models and population attributable risks for each genotype of the 6 GWAS-significant variants within the NHS and HPFS cohort samples. We did not observe substantially stronger dominance/recessive effects for any of the SNPs compared with the log-additive models that we used for our discovery analyses. We conducted a haplotype analysis for the 2 independent associations in the ABCG8 locus. In Supplementary Table 7 , we show the associations of 6 different haplotype combinations at rs11887534 (C/G) and rs4245791 (T/C). We observed that the presence of at least 1 C-T haplotype at this locus (ie, the C allele at rs11887534 and the T allele at rs4247591) was associated with a substantial increase in the risk of gallstone disease in both males and females, compared with individuals without the CT haplotype. We confirmed using the haplotype analysis that rs11887534 is likely to be the main driver of the ABCG8 association with gallstone disease risk. We did not observe any evidence for gene-gene interactions (Supplementary Table 8 ), after correcting for multiple Odds ratio were obtained from fixed-effect meta-analysis of study-specific effect size estimates adjusted for age and sex in each discovery and replication study. c Heterogeneity (het) I 2 and P values from fixed-effects meta-analysis. e Calculated using random-effects meta-analysis (if discovery P heterogeneity < .05). comparisons. There was no evidence of confounding of genetic associations after adjusting for self-reported hypercholesterolemia, intake of cholesterol-lowering drugs (ever/ never) in the NHS and HPFS cohorts, or for postmenopausal hormone therapy in the NHS cohort (Supplementary Table 9 ). The UGT1A1 SNP rs6742078 did not show an overall association with gallstone disease in log-additive models of our discovery data set (P < .114). However, in the NHS and the HPFS cohorts, we replicated the previously reported recessive mode of effect for rs6742078 TT genotype carriers with stronger evidence for association among size among males (OR, 1.45; 95% CI, 1.14-1.85; P ¼ .00284), compared with females (OR, 1.16; 95% CI, 1.00-1.34; P ¼ .0498) 17, 39 (Supplementary Table 10 ).
After multiple comparisons correction, genetic variants associated with nonalcoholic fatty liver disease were not observed to be associated with overall gallstone disease in our GWAS meta-analysis (data not shown).
Expression QTL and ENCODE Regulatory Analyses of Discovered Loci
Queries of gallstone index and proxy (R 2 > 0.8 and P < 5 Â 10 -6 ) SNPs showed that several are strong eQTLs (Supplementary Table 11 ), with some of these located within ENCODE regulatory elements (Supplementary  Table 12 ). Few gene expression studies, and no eQTL studies, have been conducted in gallbladder tissues. Gallstone index SNPs or proxies were the strongest eQTL for TM4SF4 (in liver), ABCG8 (in adipose), SULT2A1 (in liver, brain, and lung), C2orf16 (in liver), and LITAF (in liver, brain, and adipose) (Supplementary Table 13 ). Studies that have examined associations between SNPs and metabolite levels or ratios in blood have shown that rs2547231 and rs1260326 are highly significantly associated with ratios of metabolites in the cholesterol metabolism pathway (Supplementary Table 14) . 40 Results of RNA sequencing from 4 human gallbladders (3 healthy controls and 1 patient with chronic gallstones) and 1 liver sample from the gallstone patient are reported in Table 3 . The top GWAS loci ABCG5/8, SULT2A1, GCKR, and CYP7A1 had higher expression in liver, compared with the gallbladder, suggesting that they may influence the composition of bile. In contrast, TM4SF4 showed higher expression in gallbladder than the liver, with expression nearly twice as high in the chronic gallstones gallbladder as in the 3 normal samples (Table 3 and Supplementary Figure 5) , suggesting a local mechanism of action for this gene in gallbladder.
Discussion
In this large-scale, genome-wide association meta-analysis, we discovered 4 novel susceptibility loci (SULT2A1, TM4SF4, GCKR, and CYP7A1) and confirmed 1 known locus (ABCG8). The only previous GWAS of gallstone disease, comprising 280 cases and 360 controls in the discovery cohort, identified rs11887534 in ABCG8 as associated with gallstone disease. 15 In addition to confirming this association, we observed an independent association of rs4245791, an intronic variant in ABCG8, consistent with results from previous fine-mapping efforts. 41 Thus, there are at least 2 independent gallstone risk variants at the ABCG8 locus. The biological role of ABCG5/8 is to facilitate efflux of cholesterol from enterocytes and hepatocytes into the intestine and bile, respectively. 42 Therefore, genetic variants in ABCG5/8 that increase the risk of gallstone disease would be expected to confer a gain-of-function because high bile cholesterol concentration promotes the formation of cholesterol gallstones. 7 Indeed, the gallstone-associated H-allele of D19H has been shown to increase cholesterol efflux approximately 3-fold in vitro, and the gallstone-associated allele of rs4245791 has been associated with increased messenger RNA levels (ie, a gain-of-function effect). 37, 43 A third independent association within 5 Mb of rs11887534, mapped to DYNC2LI1, was identified, but was not carried forward to replication owing to limited capacity. DYNC2LI1 is a component of cilia structure, and potentially relevant because primary cilia of cholangiocytes regulate osmolarity and flow of bile. 44 Several of the newly discovered loci are in or near genes known to play a role in cholesterol or bile acid metabolism (Supplementary Table 9 and Figure 3) . Association of the discovered SNPs with the genes was made on the basis of the following: (1) missense mutations as a result of the variant such as D19H in ABCG8 and P446L in GCKR, or (2) mapping of the SNP in the intron of the gene, coupled with strong evidence of association from eQTL (TM4SF4 and SULT2A1) and mQTL data (GCKR and SULT2A1), or (3) genomic proximity to genes with strong evidence of relevance in cholesterol/bile acid metabolism pathways (eg, CYP7A1). GCKR regulates the conversion of glucose to glucose-6-phosphate in the liver. The GCKR P446L variant associated with gallstone disease, even after adjustment for BMI, has been associated with other phenotypes/traits, including lipid levels, glycemic traits, and type 2 diabetes. We postulate that P446L may influence the risk of gallstone disease by increasing the availability of cholesterol to the liver (via high endogenous synthesis), thereby increasing cholesterol concentration in the bile. [45] [46] [47] We also identified rs6471717 near CYP7A1, associated with gallstone disease. Inside the liver, the rate-limiting step in the conversion of cholesterol to primary bile acids is catalyzed by the enzyme CYP7A1. 48 Thus, genetic variation influencing CYP7A1 activity may influence gallstone disease both via increased cholesterol and by decreased bile acid levels. In support of this, individuals homozygous for deleterious mutations in CYP7A1 suffer from premature gallstone disease. 49 SULT2A1 catalyzes the conjugation of sulfates to a wide range of steroids and bile acids before biliary excretion. 50 Bile acids help to solubilize biliary cholesterol, and thus prevent gallstone formation. Altered hepatic sulfation of bile acids caused by genetic variation in SULT2A1 may influence bile acid metabolism and, in turn, biliary levels of bile acids, and, ultimately, the risk of gallstone formation. The rs2547231 variant near SULT2A1 has been associated with SULT2A1 expression, 38 and with the ratio of 2 products of SULT2A1 (X-11440 and androsten-3b,17b-diol disulfate 2). 40 Finally, we found that an intronic variant in TM4SF4 was associated significantly with gallstone disease. TM4SF4 encodes transmembrane 4 L 6 family member 4, which has been implicated in liver regeneration as well as pancreas development. 51 The role of TM4SF4 in gallstone disease has yet to be examined. TM4SF4 was identified as expressed in liver via eQTL results, with evidence for binding of liverregulatory elements in ENCODE project data. Furthermore, our RNA sequencing data showed that TM4SF4 is highly expressed in gallbladder tissue, particularly in the chronic gallstone disease sample. Queries of the Protein Atlas also confirmed the TM4SF4 RNA and protein is expressed most highly in glandular cells of the gallbladder, duodenum, and small intestine, as well as liver bile duct and hepatocytes. 52 The major strength of this study was the large discovery and replication data sets compared with the only prior gallstone GWAS. However, several limitations are noteworthy. First, we did not have information on gallstone composition (cholesterol/pigment/mixed), and could not discern between stone types. Second, gallstone case definitions varied across cohort settings. However, this concern is minimized by the observation that ABCG8 D19H, a known susceptibility locus, showed similar risk associations in most subcohorts. Third, the majority of studies defined gallstones as a history of gallstones or prior cholecystectomy. We expect this led to under-representation of asymptomatic gallstones (w80% of all gallstones are asymptomatic) and would bias toward the null hypothesis. However, because symptomatic gallstone cases require medical interventions, their over-representation may lead to the discovery of markers that have more clinical relevance. Fourth, in ethnicity-specific analyses, we observed an opposite direction of association among European vs African/Hispanic ancestry individuals for rs1260326, which suggests that this variant may not be truly causal, but may be tagging the true causal SNPs, and owing to differences in linkage disequilibrium patterns or haplotype structures across populations, this correlation may be direct in one population and inverse in the other. Nevertheless, the replication of these loci in diverse populations reinforces the importance of these loci in gallstone disease owing to marginal consistent associations across ethnicities. Fifth, another limitation of this study was the relatively small sample size of available RNA sequencing data, which limited our ability to determine whether cis genes were expressed in our tissues of interest. However, to our knowledge, there is no database that reports eQTL results for gallbladder tissue and, with this small sample, we could not derive conclusive evidence of comparative expression levels in gallbladder vs liver. Sixth, in the absence of functional studies, the hypothesized associations between SNPs and the genes based on bioinformatics/eQTL data may be speculative, and the true mechanisms by which these SNPs may impact gallstone disease may have been missed. Seventh, we used log-additive models to assess associations with gallstone disease. This may have reduced our ability to detect genetic associations that follow other modes of inheritance. Finally, we may not have been able to detect rare causal alleles in linkage disequilibrium with the most significant GWAS SNPs because conditional analysis using genome-wide complex trait analysis requires a large reference sample to estimate linkage disequilibrium. In summary, this GWAS meta-analysis of previously genotyped cohorts discovered novel SNPs associated with gallstone disease in European ancestry individuals from 4 distinct and biologically plausible loci. These genetic variants were replicated in independent samples, bringing the total number of GWAS-identified lithogenic loci to 5. Further studies addressing the functionality of these novel candidate genes are warranted to establish their causal role in gallstone development. The data set from Vanderbilt University Medical Center used for the analyses described were obtained from Vanderbilt's DNA Biobank, which is supported by institutional funding and by the Vanderbilt CTSA grant ULTR000445 from NCATS/National Institutes of Health. Genotyping of the Vanderbilt DNA Biobank samples was performed by Vanderbilt Technologies for Advanced Genomics (VANTAGE) which is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Vision Center (P30 EY08126), and the National Institutes of Health/National Center for Research Resources (NCRR) (G20 RR030956). In addition, funding also was received through the National Human Genome Research Institute (NHGRI) (U01HG006378). The Women's Genome Health Study is supported by HL043851 and HL080467 from the National Heart, Lung, and Blood Institute, by CA047988 from the National Cancer Institute, the Donald W. Reynolds Foundation, and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen, Inc, Thousand Oaks, CA.
Supplementary Material
The Copenhagen General Study Population and Copenhagen City Heart Study were supported by the Danish Medical Research Council (10-083788) Genotyping in the Women's Genome Health Study sample was performed using the HumanHap300 Duo "þ" chips or the combination of the HumanHap300 Duo and iSelect chips (Illumina, San Diego, CA) with the Infinium II protocol. 1 In either case, the custom SNP content was the same; these custom SNPs were chosen without regard to MAF to saturate candidate genes for cardiovascular disease as well as to increase coverage of SNPs with known or suspected biological function (eg, disease association, nonsynonymous changes, substitutions at splice sites, and so forth). For quality control, all samples were required to have successful genotyping using BeadStudio v. 3.3 software (Illumina) for at least 98% of the SNPs. A subset of 23,294 individuals were identified with self-reported European ancestry that could be verified on the basis of multidimensional scaling analysis of identity by state using 1443 ancestry informative markers in PLINK version 1.06. In the final data set of these individuals, a total of 339,596 SNPs were retained with a MAF greater than 1%, successful genotyping in 90% of the subjects, and deviations from Hardy-Weinberg equilibrium not exceeding a P value of 10 -6 in significance. Among the final 23,294 individuals of verified European ancestry, genotypes for a total of 2,608,509 SNPs were imputed from the experimental genotypes for 340,349 SNPs and linkage disequilibrium relationships implicit in the HapMap r. 22 optometrists, 2218 osteopathic physicians, and 1600 podiatrists). The study was approved by the institutional review board on the use of human subjects in research of the Harvard School of Public Health in Boston.
In accordance with previous work, the presence of cholecystectomy or self-reported gallstones in NHS, NHS II, and HPFS were used to define cases for the present study. 2 These measures have been validated with high precision previously. 2 Gallstone cases and noncases for whom genotyping data were available from 12 studies for different primary traits within these Harvard cohorts were included in analysis for the present study. The primary traits were as follows: breast cancer, 3 pancreatic cancer, 4 glaucoma, 5 endometrial cancer, 6 colon cancer, 7 ovarian cancer, glioma, 8 prostate cancer, 9 type 2 diabetes, 10 coronary heart disease, 11 kidney stone, gout, and mammographic density.
12
Study participants from 3 broad platform categories-the earlier generation of Illumina arrays (HumanHap), the Illumina OmniExpress array, and Affymetrix 6.0 array, were grouped into 3 nonoverlapping data sets: HumanHap comprising 6 GWAS data sets, OmniExpress comprising 4 GWAS data sets, and Affymetrix 6.0 comprising 2 GWAS data sets. Imputation was performed separately for the 3 data sets using the 1000 Genomes Project ALL Phase I Integrated Release Version 3 Haplotypes excluding monomorphic and singleton sites as reference panel. We obtained data set-specific effect size estimates for the risk of gallstone disease by logistic regression analysis assuming logadditive genetic effects, adjusting for age, cohort (includes sex), primary trait, and top for eigenvectors. We further adjusted for BMI in the sensitivity analysis. All analyses were performed using ProbABEL. 13 Framingham Heart Study. The Framingham Heart
Study is a prospective community-based observational study that aims to investigate risk factors for cardiovascular disease initiated in 1948 by enrollment of the original cohort (n ¼ 5209). 14 In 1971, the children of the original cohort and their spouses were enrolled in the offspring cohort (n ¼ 5124). 15 For the present study we used data from both the original and offspring cohorts. Cases were identified as having a history of gallstones based on questionnaires asking direct questions about prior gallstones, gallbladder disease, or gallbladder surgery. Such questionnaires were available at examination 12 (1971-1974 ; mean age, 64 years), 13, 17, and 18 (1983-1985 ; mean age, 74 years) for the original cohort, and for examination 6 (1995-1998 ; mean age, 59 years) and 7 (1998-2001 ; mean age, 62 years) for the offspring cohort. Cases were defined as cases from the day when they first replied "yes" to any of the questions, and controls were defined as controls after the last examination during which they had been consecutively free of gallbladder disease. DNA was extracted and genotyped for consenting FHS participants with Affymetrix , SNP call rate greater than 97.0%, MISHAP test P value greater than 1.0 3 10 -9 , and Mendelian errors less than 100.
Rotterdam study. The Rotterdam Study is a prospective cohort study in a suburb (Ommoord) of Rotterdam, The Netherlands. 16 Between 1990 and 1991, all inhabitants aged 55 years and older were invited to participate. In total, 7983 inhabitants agreed to participate (response rate, 78%). At baseline, participants were asked about a history of gallstone disease. Furthermore, they were linked to a hospital admission registry in the region for cases of cholelithiasis, gallbladder disease, cholecystitis, cholecystectomy, or biliary obstruction (ICD codes, 574-576). A total of 5974 Caucasian participants were genotyped successfully (Illumina 550K 1987-1989, 1990-1992, 1993-1995, 1996-1998, and 2011-2013) . For the present study, we analyzed prevalent, self-reported cases at the study's baseline examination (1987) (1988) (1989) . Information regarding prevalent gallbladder disease at baseline was ascertained retrospectively during the medical history telephone interview (1994) (1995) (1996) . 17 During the interview, participants were asked 2 questions: "Have you ever been diagnosed by a doctor as having gallstones or a gallbladder attack?" and "At what age were you first told you had a gallbladder problem?" Participants who responded "yes" to the first item and whose response to the second item was an age younger than their age at the baseline examination were defined as having prevalent gallbladder disease at baseline. A participant's baseline status was set to missing if he/she failed to complete the follow-up medical history interview. DNA was extracted at baseline or at the second visit. A genome-wide scan was conducted with the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix) in almost the whole ARIC cohort. Quality control (QC) at SNP level included exclusion of SNPs for not passing laboratory QC, no chromosome location, monomorphic, call rate less than 95%, and autosomal SNPs with a Hardy-Weinberg equilibrium P value less than 10 -6 . Imputation to approximately 2.5 million autosomal SNPs identified in HapMap phase II CEU samples was performed using MACH (v1.0.16). 18 SNPs that met the following criteria were used in the following imputation: MAF of 1% or greater, call rate 95% or greater, and a Hardy-Weinberg equilibrium P value of 10 -5 or greater. In the primary analysis, we used a logistic regression model with gallbladder disease as the outcome, assuming an additive genetic effect for SNP dosage and adjusted for age, sex, and field centers. We further adjusted for BMI in the sensitivity analysis. All analyses in ARIC were performed by ProbABEL. 13 Vanderbilt University DNA Biobank case-control study. Cases and controls were identified from the Vanderbilt University DNA Biobank, which holds data on DNA extracted from blood remaining from routine clinical testing at Vanderbilt University hospital. 19 The Vanderbilt DNA Biobank is linked to the Vanderbilt electronic health record, which includes discharge diagnoses from all hospitalizations registered on the ICD-9. 20 For the present study, we identified cases as having 2 or more ICD-9 codes 574.X (calculus of gallbladder with acute cholecystitis) or a his ) that were not performed in conjunction with other intra-abdominal surgeries. Controls comprised an age-and sex-matched sample free from any prior gallstone diagnosis (ICD-9 codes 574.X) or related procedures. All cases and controls were reviewed manually; a positive predictive value greater than 95% was identified for both cases and controls. Relevant ethical committees approved the study.
SHIP and SHIP-TREND cohorts. SHIP and SHIP-TREND are 2 independent cohorts from the Study of Health in Pomerania. The SHIP cohort comprised 4308 randomly selected individuals aged 20-79 years from the general population in the Pomerania district in Germany. 21 The first examination of the SHIP cohort was performed between 1997 and 2001. Another sample of 4420 adults aged 20-79 years subsequently was included in the SHIP-TREND cohort (first examination in 2008-2012). A total of 4081 SHIP and 986 SHIP-TREND subjects with complete GWAS information underwent an abdominal ultrasound (prevalent gallstones: SHIP, n ¼ 843; SHIP-TREND, n ¼ 67) and a full physical examination (exclusions owing to missing ultrasound data or cholecystectomy scar: SHIP, n ¼ 104; SHIP-TREND, n ¼ 101). Before study participation, all individuals provided written, informed consent.
PopGen case-control study. A community-based sample was recruited via the local population registry between 2005 and 2007 and underwent an additional physical examination between 2010 and 2012 at the PopGen facilities that included an abdominal ultrasound by a trained physician. All cases with gallstone disease had undergone cholecystectomy (N ¼ 60) or were diagnosed with cholecystolithiasis (N ¼ 62) using B-mode ultrasonography. The gallstone-free controls were confirmed to be gallstone-free by ultrasonography. For both cases and controls, the study was restricted to probands of German ethnicity; in other words, only individuals whose parents were born in Germany were included. All cases and controls provided written informed consent before the study, and the study protocol was approved by the institutional review and ethics committees of the Kiel Medical Faculty (Ethikkommission der Medizinischen Fakultät der Christian-Albrechts-Universität Kiel, #A156/03). Details about recruitment and clinical characterization have been reported previously 22, 23 (http://www.popgen.de). PopGen participants were genotypes with Affymetrix 6.0 arrays. PopGen samples were imputed with IMPUTEv2 and ShapeITv1 using default parameters based on the 1000 Genomes phase I haplotypes (build 37). Original files were preprocessed using the following measures: variants with MAF less than 0.5% or INFO less than 0.1 were removed.
Kiel case-control replication study. German cases were recruited through clinical centers at Kiel University and all had undergone cholecystectomy for cholecystolithiasis. German controls all were confirmed to be gallstone-free by ultrasonography and were drawn from a randomly selected urban population sample. Details about recruitment and clinical characterization have been reported previously for cases 24 and controls. 25 Written informed consent was obtained from all study participants. The study was approved by the research Ethics Committee of Kiel University Hospital and the Baden-Württemberg General Medical Council (Landesärztekammer BadenWürttemberg).
Copenhagen General Study Population and Copenhagen City Heart Study. Participants in 2 prospective studies of the Danish general population, the Copenhagen General Study Population and Copenhagen City Heart Study, were combined, yielding a total of 60,988 participants, including 3599 with symptomatic gallstone disease. Studies were approved by institutional review boards and Danish ethical committees, and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from participants. All participants were white and of Danish descent, as determined by the National Danish Person Registration System. There was no overlap of individuals between the studies.
The Copenhagen General Study Population 26,27 is a prospective study of the Danish general population initiated in 2003 with ongoing enrollment. Individuals are selected based on the National Danish Civil Registration System to reflect the adult Danish population aged 20-100 years. Data are obtained from a self-administered questionnaire reviewed together with an investigator at the day of attendance, a physical examination, and from blood samples including DNA extraction. We included 52,716 consecutive participants from this study in the present analysis. The Copenhagen City Heart Study 26,27 is a prospective study of the Danish general population initiated in 1976-1978 with follow-up examinations in [1981] [1982] [1983] [1991] [1992] [1993] [1994] Women's Health Initiative. The WHI is a US study focusing on common health issues in postmenopausal women. A total of 161,808 postmenopausal women aged 50-79 years old were recruited between 1993 and 1998, including 12,151 self-identified African Americans and 5469 self-identified Hispanic Americans. Details of the study design and cohort characteristics have been described previously. 28 Clinical information was collected by self-report and physical examination. All participants provided written informed consent as approved by local Human Subjects Committees. A cohort of 8515 self-identified African American and 3642 self-identified Hispanic American participants from WHI, who had consented to genetic research, were selected for the WHI SNP Health Association Resource project (n ¼ 12,157) and genotyped on the Affymetrix 6.0 array. Genotype quality control criteria included call rate, concordance rates for blinded and unblinded duplicates, and sex discrepancy. Furthermore, individuals whose genetic ancestries differed from self-reported ethnicities and 1 individual from each close relative pair were excluded. In total, 11,740 individuals passed all genotype and sample QC criteria (8153 African American 3587 Hispanic American). Details of the QC procedures have been described in previous WHI-SNP Health Association Resource studies. 29, 30 The sample analyzed in the current study included African American and Hispanic American WHI women for whom both DNA samples were genotyped successfully, and for which information was available for gallbladder disease status as well as study covariates.
Expression QTL and ENCODE regulatory analyses. The eQTL SNPs with gene expression associations with a P value less than 5 Â 10 -6 were queried for overlap with ENCODE regulatory features using HaploReg v3 (http:// www.broadinstitute.org/mammals/haploreg/haploreg_v3. php). 31 Blood cell-related eQTL studies included fresh lymphocytes, 32 fresh leukocytes, 33 leukocyte samples in individuals with celiac disease, 34 whole blood samples, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] lymphoblastoid cell lines derived from asthmatic children, 50, 51 HapMap lymphoblastoid cell lines from 3 populations, 52 a separate study on HapMap CEU lymphoblastoid cell lines, 53 additional lymphoblastoid cell line population samples, [54] [55] [56] [57] [58] [59] CD19þ B cells, 60 primary PHA-stimulated T cells, 54, 57 CD4þ T cells, 61 peripheral blood monocytes, 60, 62, 63 and CD14þ monocytes before and after stimulation with lipopolysaccharide or interferon-g, 64 CD11þ dendritic cells before and after Mycobacterium tuberculosis infection, 65 and a separate study of dendritic cells before or after stimulation with lipopolysaccharide, influenza, or interferon-b. 66 MicroRNA QTLs 67 and DNase-I QTLs also were queried for lymphoblastoid cell lines. 68 Non-blood cell tissue eQTLs searched included omental and subcutaneous adipose, 35, 43, 56, 69 Additional eQTL data were integrated from online sources including ScanDB, the Broad Institute GTex browser, and the Pritchard Laboratory (eqtl.uchicago.edu). Cerebellum, parietal lobe, and liver eQTL data were downloaded from ScanDB and cis-eQTLs were limited to those with a P value less than 1.0 Â 10 -6 and trans-eQTLs with a P value less than 5.0 Â 10 -8
. The top 1000 eQTL results were downloaded from the GTex Browser at the Broad Institute for 9 tissues on November 26, 2013: thyroid, leg skin (sun exposed), tibial nerve, tibial artery, skeletal muscle, lung, heart (left ventricle), whole blood, and subcutaneous adipose. 43 All GTex results had associations with a P value less than 8.4 Â 10 -7 .
Genetic Risk Score and Discriminative Ability
In the Kiel data set, the weighted GRS ranged from -2.57 to þ4.27, with a median of -0.047. After adjusting for age, sex, and BMI, an increase in 1 SD of weighted GRS was associated with an increased risk of gallstone disease with an OR of 1.50 and a 95% CI of 1.39-1.61. The addition of weighted GRS to a risk prediction model with age, sex, and BMI, showed modest improvements in the Nagelkerke's R 2 from 0.323 to 0.351 and the area under the curve for the receiver operating characteristic plot from 0.783 to 0.798 (Supplementary Figure 4) . These improvements in risk prediction measures were similar among males and females in the Kiel cohort.
In the NHS/HPFS replication data set, the weighted GRS ranged from -2.71 to þ4.69, with a median of -0.195. The relative risk associated with a SD increase in genetic risk score was 1.33 (1.23, 1.43), after adjusting for age, sex, and BMI at blood draw. The improvement in Nagelkerke's R 2 was from 0.085 to 0.103, and improvement in the area under the curve of the receiver operating characteristic plot was from 0.663 to 0.679. The addition of a GRS yielded a greater improvement in risk prediction in the NHS (women) compared with the HPFS (men) (Supplementary Figure 4) . All cases with gallstone disease had undergone cholecystectomy or were diagnosed with cholecystolithiasis using B-mode ultrasonography; the gallstonefree controls were confirmed to be gallstone-free by ultrasonography SHIP-TREND Participants underwent an abdominal ultrasound to identify gallstones and a full physical examination (and participants were excluded because of missing ultrasound data or cholecystectomy scar) All discovery samples Replication studies CCHS and CGPS Diagnoses of symptomatic gallstone disease (ICD-8, 574-575; ICD-10, K80-K81) were collected from the National Danish Patient Registry and the National Danish Causes of Death Registry Kiel University
Hospital-based, case-control study in which German cases were recruited through clinical centers at Kiel University and all had undergone cholecystectomy for cholecystolithiasis German controls all were confirmed to be gallstone-free by ultrasonography and were drawn from a randomly selected urban population sample WHI Cases were identified based on questionnaires asking about prior gallstones or gallbladder disease
Supplementary NOTE. All eQTL results (P < 1.0 Â -05 ) for gallstone main index and replication SNPs are shown that display concordance between index, gallstone-selected eSNP, and best-known eSNP. Concordance was defined as either the same SNP or SNPs in which all 3 pairwise relationship (between eSNP, index SNP and best eSNP) with r 2 > 0.8 in HapMap CEU populations as defined by querying SNAP (http://www.broadinstitute.org/mpg/snap/).
